title: Nitric oxide, oxygen, and prostacyclin in children with pulmonary hypertension.
abstract: OBJECTIVE
  To test the vasodilatory response of the pulmonary vascular bed in children with pulmonary hypertension.
  
  
  METHODS
  Prospective dose response study in which the effects of inhaled nitric oxide (NO) are compared with those of oxygen and intravenous prostacyclin.
  
  
  METHODS
  The vasodilator test was performed in 20 patients in whom mean pulmonary artery pressure (PAPm) was > or = 40 mm Hg and /or pulmonary vascular resistance index was > or = 4 Um2. Haemodynamic effects of inhaled NO (20, 40, and 80 ppm) at a fractional inspired oxygen (FiO2) value of 0.3, pure oxygen, oxygen at FiO2 0.9-1.0 combined with NO as above or with intravenous prostacyclin at 10 and 20 ng/kg/min were measured.
  
  
  RESULTS
  NO decreased PAPm with a dose response from 20 to 40 ppm (mean change at 40 ppm-5.50, 95% confidence interval (CI) -7.98 to -3.02 mm Hg. Maximal decrease in the ratio of pulmonary to systemic vascular resistance was achieved with a combination of NO 80 ppm and oxygen (-0.18, 95% CI -0.26 to -0.10). Increase in the pulmonary flow index was greatest with pure oxygen in those with an intracardiac shunt (8.52, 95% CI -0.15 to 17.20 l/min/m2). Neither NO nor oxygen altered systemic arterial pressure but intravenous prostacyclin lowered systemic arterial pressure and resistance.
  
  
  CONCLUSIONS
  NO selectively reduces pulmonary vascular resistance and pressure maximally at 40 ppm. Oxygen reduces pulmonary vascular resistance and NO potentiates this reduction without affecting the systemic circulation. Prostacyclin vasodilates the pulmonary and the systemic circulations.
authors.affiliation: Department of Paediatric Cardiology, Hospital for Children and Adolescents, Helsinki University Central Hospital, Finland.
authors.forename: M I
authors.initials: MI
authors.lastname: Turanlahti
authors.forename: P O
authors.initials: PO
authors.lastname: Laitinen
authors.forename: S J
authors.initials: SJ
authors.lastname: Sarna
authors.forename: E
authors.initials: E
authors.lastname: Pesonen
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D011464:Epoprostenol / Q000627:therapeutic use*; D005260:Female; D006330:Heart Defects, Congenital / Q000150:complications; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D007223:Infant; D007262:Infusions, Intravenous; D008297:Male; D009569:Nitric Oxide / Q000627:therapeutic use*; D010100:Oxygen / Q000627:therapeutic use*; D011652:Pulmonary Circulation / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D014665:Vasodilator Agents; D009569:Nitric Oxide; D011464:Epoprostenol; D010100:Oxygen